# US 2010/0145026 A1 · Antibody for ADCC And Inducing Cytokine Production

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0145026 A1
- Document ID: US20100145026A1
- Status: Published application
- Kind: A1
- Application number: 12/576,202
- Filed: 2009-10-08
- Published: 2010-06-10
- Earliest claimed: 2002-09-13
- Assignees: Lfb Biotechnologies
- Inventors: Christophe de ROMEUF; Arnaud GLACET; Jacques LIROCHON; Dominique BOUREL
- Web page: https://patentgrep.com/patent/US20100145026A1

## CPC

- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K 2039/505: {comprising antibodies}
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention concerns chimeric monoclonal antibodies, humanized or human produced in selected cell lines, said antibodies exhibiting high affinity for the CD16 receptor of effector cells of the immune system and hence capable of inducing high ADCC, but also the property of inducing cytokine and interleukin secretion, in particular IFNγ, which can enhance the ADCC activity of effector cells and hence be used for treating cancers and infections by pathogenic agents.

## Claims

### Claim 1

A human or humanized chimeric monoclonal antibody produced in a cell line selected for its properties of particular glycosylation of the Fc fragment of an antibody, or the glycan structure of which has been modified ex vivo, said antibody having an FcyRIII (CD16) -type ADCC rate of greater than 60%, 70%, 80% or preferably greater than 90%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody, characterized in that it has an ability to induce a rate of production of at least one cytokine by the Jurkat CD16 cell or a CD16 receptor-expressing effector cell of the immune system of greater than 60%, 100%, or preferably greater than 200%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody, and wherein said human, humanized, or chimeric monoclonal antibody is an anti-HLA-DR antibody.

### Claim 2 (depends on 1)

The antibody as claimed in claim 1, wherein it has an ADCC rate of greater than 100% at a concentration of 10 ng/ml or less, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody, and a rate of production of at least one cytokine by a CD16 receptor-expressing effector cell of the immune system of greater than 1000% at a concentration of 10 ng/ml or less, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody.

### Claim 3 (depends on 1)

The antibody as claimed in claim 1, wherein the cytokines that are released are interleukins.

### Claim 4 (depends on 1)

The antibody as claimed in claim 1, wherein cytokines that are released are interferons.

### Claim 5 (depends on 1)

The antibody as claimed in claim 1, wherein the cytokines that are released are tissue necrosis factors (TNFs).

### Claim 6 (depends on 1)

The antibody as claimed in claim 1, wherein the antibody selected has the ability to induce the secretion of at least one cytokine chosen from IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, TNFa, TGFp, IP10 and IFNy, by the CD16 receptor-expressing effector cells.

### Claim 7 (depends on 1)

The antibody as claimed in claim 1, wherein the antibody selected has the ability to induce the secretion of IL-2 by CD16 receptor-expressing effector cells of the immune system.

### Claim 8 (depends on 1)

The antibody as claimed in claim 1, wherein the effector cell is a CD16 receptor-expressing Jurkat cell or by a leukocytic cell, in particular of the NK (natural killer) family, or by cells of the monocyte-macrophage group.

### Claim 9 (depends on 1)

The antibody as claimed in claim 1, wherein it is produced in a cell line of the rat myeloma type, in particular YB2/0.

### Claim 10 (depends on 1)

The antibody as claimed claim 1, wherein it is directed against an antigen of a pathological cell or of an organism that is pathogenic for humans, in particular against an antigen of a cancer cell.

### Claim 11 (depends on 10)

The antibody as claimed in claim 10, wherein its specificity is anti-Rhesus D of human red blood cells.

### Claim 12 (depends on 11)

The antibody as claimed in claim 11, wherein it is an anti-HLA-DR.

### Claim 13 (depends on 12)

The antibody as claimed in claim 12, wherein it has an ADCC rate of greater than 100% at a concentration of 10 ng/ml or less, and a rate of IL-2 production by a CD16-receptor-expressing effector cell of the immune system of greater than up to 1000% at a concentration of 10 ng/ml or less, compared with the same antibody expressed in the CHO line, the expression line for Remitogen®.

### Claim 14 (depends on 12)

The antibody as claimed in claim 12, wherein it is produced in a rat myeloma line, in particular YB2/0.

### Claim 15 (depends on 10)

The antibody as claimed in claim 10, wherein it is an anti-CD20.

### Claim 16 (depends on 15)

The antibody as claimed in claim 15, wherein it has an ADCC rate of greater than 100% at a concentration of 10 ng/ml or less, and a rate of IL-2 production by a CD16-receptor-expressing effector cell of the immune system of greater than up to 1000% at a concentration of 10 ng/ml or less, compared with Rituxan®.

### Claim 17 (depends on 15)

The antibody as claimed in claim 15, wherein it is produced in a rat myeloma line, in particular YB2/0.

### Claim 18 (depends on 10)

The antibody as claimed in claim 10, wherein it is selected from anti-Ep-CAM, anti-KIR3DL2, anti-VEGFR, anti-HER1, anti-HER2, anti-GD, anti-GD2, anti-GD3, anti-CD23, anti-CD30, anti-CD33, anti-CD38, anti-CD44, anti-CD52, anti-CA125 and anti-ProteinC; anti-Ep-CAM, anti-HER2, anti-CD52, anti-HER1, anti-GD3, anti-CA125 anti-GD, anti-GD2, anti-CD23 and antiProteinC; antivirals: HBV, HCV, HIV and RSV, anti-idiotypes specific for inhibitors, for example forclotting factors including FVIII and FIX.

### Claim 19 (depends on 1)

The method of using an antibody as claimed in claim 1, for producing a medicinal product intended for the treatment of cancers and of infections with pathogenic agents.

### Claim 20 (depends on 1)

The method of using an antibody as claimed in claim 1, for producing a medicinal product intended for the treatment of cancers of MHC class II-positive cells, in particular B-cell lymphomas, acute B-cell leukemias, Burkitt's lymphoma, Hodgkin's lymphoma, myeloid leukemias, T-cell lymphomas and leukemias, non-Hodgkin's lymphomas, and chronic 15 myeloid leukemias.

### Claim 21 (depends on 1)

The method of using an antibody as claimed in claim 1, for producing a medicinal product intended to induce the expression of TNF, IP10 and IL-6 by natural effector cells of the immune system, said medicinal product being useful in particular for the treatment of cancer and of infections.
